Percutaneous Deep Vein Arterialisation (pDVA) with the LimFlow System offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent study published in the Journal of Critical Limb Ischemia.
Peter Schneider, professor of surgery at the University of California (San Francisco, USA) and co-author of the published article, said: “The cost-effectiveness analysis builds on recently published 12-month data from the PROMISE I study by showing that pDVA with the LimFlow System can be a high-value therapy alternative to the status quo for no-option CLTI patients.
“This research highlights the health economic benefits of reducing amputations and the need to offer patients a better alternative worldwide.”
The findings highlighted significant and promising data from cost-effectiveness analysis comparing pDVA with the LimFlow System to the status quo treatment for no-option CLTI patients, according to the study authors.
The status quo was defined by a meta-analysis conducted by the Yale Cardiovascular Research Group on no-option patient outcomes from other reputable studies ranging from 2006 to 2018, which is pending publication in the Journal of Critical Limb Ischemia.
The comparative analysis demonstrates that expected outcome improvements with pDVA justify its incremental costs and qualifies it as a “high-value” therapy per established willingness-to-pay thresholds.
Dan Rose, CEO of LimFlow, added: “Avoiding major amputation is a key treatment goal in CLTI due to its associated high costs, loss of functional status and quality of life, and high mortality.
“The analysis using data from PROMISE I demonstrates our technology can provide significant clinical and health-economic value to patients and healthcare providers who are drastically underserved by the status quo.”
